FDA approves Dechra Pharma's generic antibiotic
Dechra Pharmaceuticals obtained its first approval for a product from its recently acquired US business Putney.
Dechra Pharmaceuticals
3,866.00p
08:01 16/01/24
0.00%
0.00p
FTSE 250
20,522.81
16:38 14/11/24
n/a
n/a
FTSE 350
4,459.02
16:38 14/11/24
n/a
n/a
FTSE All-Share
4,417.25
16:54 14/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,794.96
16:38 14/11/24
0.96%
187.95
The drug firm hailed the approval of its generic antibiotic by the US Food and Drug Administration, seeing it as confirmation of the capabilities of its specialist pharma team.
Its product would be the first generic to enter a substantial antibiotic market, the company said in a statement.
Commenting on the approval Dechra's Chief Executive Officer, Ian Page said: "We are delighted to receive this approval which provides excellent growth opportunity for our US team and underpins our confidence in the strength of the recently acquired Putney business whilst further enhancing Dechra's position in the US market."